$GCTK
GlucoTrack Inc Stock $gctk

$gctk Overview Financials Valuation SEC Filings Company Website

2023 Q1 Form 10-K Financial Statement

#000149315223010356 Filed on March 31, 2023

Income Statement

Concept	2023 Q1	2022 Q4	2022
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$642.0K	$683.0K	$2.462M
YoY Change	1.42%	-11.41%	10.9%
% of Gross Profit
Research & Development	$642.0K	$604.0K	$1.967M
YoY Change	39.57%	-17.6%	10.63%
% of Gross Profit
Depreciation & Amortization	$4.000K	$4.000K	$23.00K
YoY Change	-55.56%	-55.56%	-45.24%
% of Gross Profit
Operating Expenses	$1.284M	$1.287M	$4.432M
YoY Change	17.47%	-14.43%	9.7%
Operating Profit	-$1.284M		-$4.432M
YoY Change	17.47%		9.7%
Interest Expense	-$2.000K	$13.00K	$11.00K
YoY Change		160.0%	-57.69%
% of Operating Profit
Other Income/Expense, Net		-$13.00K	-$14.00K
YoY Change		85.71%	-73.58%
Pretax Income	-$1.286M	-$1.287M	-$4.435M
YoY Change	17.66%	-14.54%	9.05%
Income Tax
% Of Pretax Income
Net Earnings	-$1.286M	-$1.287M	-$4.435M
YoY Change	17.66%	-14.54%	9.05%
Net Earnings / Revenue
Basic Earnings Per Share	-$0.08		$0.29
Diluted Earnings Per Share	-$0.08	-$0.08	-$0.29
COMMON SHARES
Basic Shares Outstanding	15.50M shares	15.48M shares	15.47M shares
Diluted Shares Outstanding	15.50M shares		15.47M shares

Balance Sheet

Concept	2023 Q1	2022 Q4	2022
SHORT-TERM ASSETS
Cash & Short-Term Investments	$1.003M	$2.312M	$2.312M
YoY Change	-79.06%	-61.86%	-61.86%
Cash & Equivalents	$1.003M	$2.312M	$2.312M
Short-Term Investments
Other Short-Term Assets	$203.0K	$67.00K	$67.00K
YoY Change	-54.07%	55.81%	55.81%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$1.206M	$2.379M	$2.379M
YoY Change	-76.95%	-61.03%	-61.03%
LONG-TERM ASSETS
Property, Plant & Equipment	$35.00K	$40.00K	$40.00K
YoY Change	-55.13%	-42.03%	-63.3%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$10.00K	$19.00K	$19.00K
YoY Change	-80.0%	-62.75%	-62.75%
Total Long-Term Assets	$45.00K	$59.00K	$59.00K
YoY Change	-64.84%	-63.13%	-63.13%
TOTAL ASSETS
Total Short-Term Assets	$1.206M	$2.379M	$2.379M
Total Long-Term Assets	$45.00K	$59.00K	$59.00K
Total Assets	$1.251M	$2.438M	$2.438M
YoY Change	-76.66%	-61.09%	-61.09%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$652.0K	$672.0K	$672.0K
YoY Change	10.51%	6.5%	6.5%
Accrued Expenses		$325.0K	$341.0K
YoY Change		1313.04%	35.32%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$1.047M	$1.013M	$1.013M
YoY Change	14.3%	14.72%	14.72%
LONG-TERM LIABILITIES
Long-Term Debt	$193.0K	$195.0K	$195.0K
YoY Change	-6.31%	-7.14%	-7.14%
Other Long-Term Liabilities	$193.0K	$0.00	$0.00
YoY Change	3116.67%	-100.0%	-100.0%
Total Long-Term Liabilities	$193.0K	$195.0K	$195.0K
YoY Change	-8.96%	-14.1%	-14.1%
TOTAL LIABILITIES
Total Short-Term Liabilities	$1.047M	$1.013M	$1.013M
Total Long-Term Liabilities	$193.0K	$195.0K	$195.0K
Total Liabilities	$1.240M	$1.208M	$1.208M
YoY Change	9.93%	8.83%	8.83%
SHAREHOLDERS EQUITY
Retained Earnings	-$103.2M	-$101.9M
YoY Change		4.55%
Common Stock	$103.2M	$103.1M
YoY Change		0.47%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$11.00K	$1.230M	$1.230M
YoY Change
Total Liabilities & Shareholders Equity	$1.251M	$2.438M	$2.438M
YoY Change	-76.66%	-61.09%	-61.09%

Cashflow Statement

Concept	2023 Q1	2022 Q4	2022
OPERATING ACTIVITIES
Net Income	-$1.286M	-$1.287M	-$4.435M
YoY Change	17.66%	-14.54%	9.05%
Depreciation, Depletion And Amortization	$4.000K	$4.000K	$23.00K
YoY Change	-55.56%	-55.56%	-45.24%
Cash From Operating Activities	-$1.313M	-$940.0K	-$3.729M
YoY Change	3.79%	-3.39%	-1.06%
INVESTING ACTIVITIES
Capital Expenditures		-$3.000K	$1.000K
YoY Change		-25.0%	-120.0%
Acquisitions
YoY Change
Other Investing Activities		$2.000K	$2.000K
YoY Change			-50.0%
Cash From Investing Activities		$5.000K	$1.000K
YoY Change		-225.0%	-200.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities
YoY Change
NET CHANGE
Cash From Operating Activities	-$1.313M	-940.0K	-$3.729M
Cash From Investing Activities		5.000K	$1.000K
Cash From Financing Activities
Net Change In Cash	-$1.318M	-935.0K	-$3.782M
YoY Change	4.19%	-4.3%
FREE CASH FLOW
Cash From Operating Activities	-$1.313M	-$940.0K	-$3.729M
Capital Expenditures		-$3.000K	$1.000K
Free Cash Flow	-$1.313M	-$937.0K	-$3.730M
YoY Change		-3.3%	-0.9%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022	dei	Entity Central Index Key EntityCentralIndexKey	0001506983
CY2022	dei	Amendment Flag AmendmentFlag	false
CY2022	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset		usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent		usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent		usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2021Q4	IGAP	Receipts On Account Of Shares ReceiptsOnAccountOfShares		usd
CY2022	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense		usd
CY2022	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable		usd
CY2022	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories		usd
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue
CY2021	IGAP	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term1 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm1
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue
CY2021	IGAP	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Exerciable In Period Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExerciableInPeriodIntrinsicValue
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod		shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
CY2022	IGAP	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term1 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm1
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue
CY2022	IGAP	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Exerciable In Period Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExerciableInPeriodIntrinsicValue
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate		pure
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate		pure
CY2022	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense		usd
CY2022Q4	IGAP	Deferred Tax Assets Tax Vacation Accrual DeferredTaxAssetsTaxVacationAccrual		usd
CY2021Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch		usd
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet		usd
CY2021Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet		usd
CY2022	dei	Document Type DocumentType	10-K
CY2022	dei	Document Annual Report DocumentAnnualReport	true
CY2022	dei	Document Period End Date DocumentPeriodEndDate	2022-12-31
CY2022	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2022	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2022	dei	Document Transition Report DocumentTransitionReport	false
CY2022	dei	Entity File Number EntityFileNumber	000-54785
CY2022	dei	Entity Registrant Name EntityRegistrantName	GLUCOTRACK, INC.
CY2022	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2022	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	98-0668934
CY2022	dei	Entity Address Address Line1 EntityAddressAddressLine1	301 Route 17 North
CY2022	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 800
CY2022	dei	Entity Address City Or Town EntityAddressCityOrTown	Rutherford
CY2022	dei	Entity Address State Or Province EntityAddressStateOrProvince	NJ
CY2022	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	07070
CY2022	dei	City Area Code CityAreaCode	201
CY2022	dei	Local Phone Number LocalPhoneNumber	842-7715
CY2022	dei	Security12b Title Security12bTitle	Common stock, par value $0.001 per share
CY2022	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2022	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2022	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2022	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2022	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2022	dei	Entity Small Business EntitySmallBusiness	true
CY2022	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2022	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2022	dei	Entity Shell Company EntityShellCompany	false
CY2022	dei	Trading Symbol TradingSymbol	GCTK
CY2022	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2022Q2	dei	Entity Public Float EntityPublicFloat	3930000	usd
CY2023Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	15503632	shares
CY2022	dei	Auditor Firm AuditorFirmId	1375
CY2022	dei	Auditor Name AuditorName	FAHN KANNE & CO. GRANT THORNTON ISRAEL
CY2022	dei	Auditor Location AuditorLocation	Tel-Aviv, Israel
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2312000	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	6062000	usd
CY2022Q4	us-gaap	Other Assets Current OtherAssetsCurrent	67000	usd
CY2021Q4	us-gaap	Other Assets Current OtherAssetsCurrent	43000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	2379000	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	6105000	usd
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	40000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	40000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	69000	usd
CY2022Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	19000	usd
CY2021Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	51000	usd
CY2022Q4	us-gaap	Assets Assets	2438000	usd
CY2021Q4	us-gaap	Assets Assets	6265000	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	672000	usd
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	631000	usd
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	23000	usd
CY2022Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	341000	usd
CY2021Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	229000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	1013000	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	883000	usd
CY2022Q4	us-gaap	Due To Officers Or Stockholders Noncurrent DueToOfficersOrStockholdersNoncurrent	195000	usd
CY2021Q4	us-gaap	Due To Officers Or Stockholders Noncurrent DueToOfficersOrStockholdersNoncurrent	210000	usd
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	17000	usd
CY2022Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	195000	usd
CY2021Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	227000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	1208000	usd
CY2021Q4	us-gaap	Liabilities Liabilities	1110000	usd
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	15500730	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	15500730	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	15470402	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	15470402	shares
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	15000	usd
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	15000	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	15000	usd
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	15000	usd
CY2022Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	103095000	usd
CY2021Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	102612000	usd
CY2022Q4	IGAP	Receipts On Account Of Shares ReceiptsOnAccountOfShares	4000	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	17000	usd
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-6000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-101901000	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-97466000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	1230000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	5155000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	2438000	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	6265000	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1967000	usd
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1810000	usd
CY2021	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	139000	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2465000	usd
CY2021	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2091000	usd
CY2022	us-gaap	Operating Expenses OperatingExpenses	4432000	usd
CY2021	us-gaap	Operating Expenses OperatingExpenses	4040000	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-4432000	usd
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-4040000	usd
CY2022	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-14000	usd
CY2021	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-53000	usd
CY2022	IGAP	Financing Income Expense Net FinancingIncomeExpenseNet	11000	usd
CY2021	IGAP	Financing Income Expense Net FinancingIncomeExpenseNet	26000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-4435000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-4067000	usd
CY2022	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-23000	usd
CY2021	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	21000	usd
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	4412000	usd
CY2021	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	4088000	usd
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.29
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.26
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	15474660	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	15450824	shares
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	8982000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-4067000	usd
CY2021	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-21000	usd
CY2021	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	38000	usd
CY2021	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	223000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	5155000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	5155000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-4435000	usd
CY2022	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	23000	usd
CY2022	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	439000	usd
CY2022	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	48000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	1230000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-4435000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-4067000	usd
CY2022	us-gaap	Depreciation Depreciation	23000	usd
CY2021	us-gaap	Depreciation Depreciation	42000	usd
CY2022	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-1000	usd
CY2021	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-42000	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	439000	usd
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	223000	usd
CY2022	IGAP	Issuance Of Restricted Shares As Compensation To Board Of Directors IssuanceOfRestrictedSharesAsCompensationToBoardOfDirectors	48000	usd
CY2021	IGAP	Issuance Of Restricted Shares As Compensation To Board Of Directors IssuanceOfRestrictedSharesAsCompensationToBoardOfDirectors	38000	usd
CY2022	IGAP	Linkage Difference On Principal Of Loans From Stockholders LinkageDifferenceOnPrincipalOfLoansFromStockholders	11000	usd
CY2021	IGAP	Linkage Difference On Principal Of Loans From Stockholders LinkageDifferenceOnPrincipalOfLoansFromStockholders	6000	usd
CY2021	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-68000	usd
CY2021	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-293000	usd
CY2022	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	28000	usd
CY2021	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	-15000	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	74000	usd
CY2021	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	-257000	usd
CY2022	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	138000	usd
CY2021	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	-172000	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-3729000	usd
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-3769000	usd
CY2022	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	2000	usd
CY2021	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	4000	usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1000	usd
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	5000	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	1000	usd
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1000	usd
CY2022	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	-54000	usd
CY2021	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	-2000	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-3782000	usd
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-3772000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	6113000	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	9885000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	2331000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	6113000	usd
CY2021Q3	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	1 for 13
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-101901000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2312000	usd
CY2022	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_84D_eus-gaap--UseOfEstimates_zXe6gKWt6yBa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top"> <td style="font-family: Times New Roman, Times, Serif; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td id="xdx_86C_zFnaKUK9i1h1" style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A.</b></span></td> <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span><span id="xdx_867_z0Zm1SfzBNWh">Use of estimates in the preparation of financial statements</span></span></b></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of the consolidated financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the dates of the financial statements, and the reported amounts of expenses during the reported periods. Actual results could differ from those estimates. As applicable to these financial statements, the most significant estimates and assumptions relate to evaluation of going concern.</span></td></tr> </table>
CY2022Q4	us-gaap	Foreign Currency Exchange Rate Remeasurement1 ForeignCurrencyExchangeRateRemeasurement1	0.284	pure
CY2021Q4	us-gaap	Foreign Currency Exchange Rate Remeasurement1 ForeignCurrencyExchangeRateRemeasurement1	0.321	pure
CY2022Q4	us-gaap	Foreign Currency Exchange Rate Translation1 ForeignCurrencyExchangeRateTranslation1	0.1162	pure
CY2021Q4	us-gaap	Foreign Currency Exchange Rate Translation1 ForeignCurrencyExchangeRateTranslation1	0.0322	pure
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2312000	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	6062000	usd
CY2022Q4	us-gaap	Restricted Cash RestrictedCash	19000	usd
CY2021Q4	us-gaap	Restricted Cash RestrictedCash	51000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	2331000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	6113000	usd
CY2022	us-gaap	Severance Costs1 SeveranceCosts1	27000	usd
CY2021	us-gaap	Severance Costs1 SeveranceCosts1	43000	usd
CY2022	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p id="xdx_849_eus-gaap--ConcentrationRiskCreditRisk_zskujEHJBvtd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top"> <td style="font-family: Times New Roman, Times, Serif; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>P.</b></span></td> <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_860_zD1o1sbKAlCj">Concentrations of credit risk</span></b></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial instruments that potentially subject the Group to concentrations of credit risk consist primarily of cash and cash equivalents, and restricted cash. Cash and cash equivalents and restricted cash are deposited with major banks in United States. Management believes that such financial institutions are financially sound, accordingly, minimal credit risk exists with respect to these financial instruments. The Group does not have any significant off-balance-sheet concentration of credit risk, such as foreign exchange contracts, option contracts or other foreign hedging arrangements.</span></td></tr> </table>
CY2022	us-gaap	Lessor Operating Lease Description LessorOperatingLeaseDescription	Generally, 75% or more of the remaining economic life of the underlying assets
CY2022	us-gaap	Lessor Operating Lease Lease Not Yet Commenced Lessee Option To Purchase Underlying Asset LessorOperatingLeaseLeaseNotYetCommencedLesseeOptionToPurchaseUnderlyingAsset	Generally, 90% or more of the fair value of the underlying asset
CY2022Q4	us-gaap	Lessor Operating Lease Term Of Contract LessorOperatingLeaseTermOfContract	P12M
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	294000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	489000	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	254000	usd
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	420000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	40000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	69000	usd
CY2022	us-gaap	Depreciation Depreciation	23000	usd
CY2021	us-gaap	Depreciation Depreciation	42000	usd
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	16000	usd
CY2021Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	98000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	325000	usd
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	131000	usd
CY2022Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	341000	usd
CY2021Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	229000	usd
CY2022	IGAP	Quarterly Payments Equals To Sales Percentage QuarterlyPaymentsEqualsToSalesPercentage	0.10	pure
CY2010Q1	us-gaap	Description Of Nature And Effect Of Significant Changes During Period Affecting Comparability DescriptionOfNatureAndEffectOfSignificantChangesDuringPeriodAffectingComparability	the Company’s Board of Directors has full authority in its discretion, from time to time and at any time, to determine (i) the designate participants; (ii) the terms and provisions of the respective award agreements, including, but not limited to, the number of share options to be granted to each optionee, the number of shares to be covered by each share option, provisions concerning the time and the extent to which the share options may be exercised and the nature and duration of restrictions as to the transferability or restrictions constituting substantial risk of forfeiture and to cancel or suspend awards, as necessary; (iii) determine the fair market value of the shares covered by each award; (iv) make an election as to the type of approved 102 Option under Israeli tax law; (v) designate the type of share options; (vi) take any measures, and to take actions, as deemed necessary or advisable for the administration and implementation of the Plan; (vii) interpret the provisions of the Plan and to amend from time to time the terms of the Plan
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	128297000	shares
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	64.46
CY2020	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2	P5Y5M1D
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	589933000	shares
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	5.2
CY2021	IGAP	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term One SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTermOne	P2Y10M17D
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	98177000	shares
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	64.64
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	620053000	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	8.05
CY2021	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2	P2Y11M26D
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	39223000	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	50.27
CY2021	IGAP	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Remaining Contractual Term3 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm3	P4Y7M24D
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	620053000	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	8.05
CY2021	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2	P2Y11M26D
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	115857000	shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	5.2
CY2022	IGAP	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm	P2Y8M4D
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	735910000	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	7.6
CY2022	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2	P2Y1M6D
CY2021	us-gaap	Income Tax Reconciliation Tax Settlements IncomeTaxReconciliationTaxSettlements	4067000	usd
CY2022Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	14000000	usd
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	245535000	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	12.4
CY2022	IGAP	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Remaining Contractual Term3 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm3	P2Y6M29D
CY2022Q4	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions	735910	shares
CY2022Q4	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions	245535	shares
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.7215	pure
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.4921	pure
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.025	pure
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.025	pure
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P3Y
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P3Y
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice	5.2
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice	5.2
CY2022Q4	us-gaap	Share Price SharePrice	1.89
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	186000	usd
CY2022	us-gaap	Deferred Compensation Arrangement With Individual Maximum Contractual Term1 DeferredCompensationArrangementWithIndividualMaximumContractualTerm1	P0Y8M19D
CY2022	us-gaap	Income Tax Reconciliation Tax Settlements Foreign IncomeTaxReconciliationTaxSettlementsForeign	907000	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1967000	usd
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1810000	usd
CY2021	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	139000	usd
CY2022	us-gaap	Income Tax Reconciliation Tax Settlements Domestic IncomeTaxReconciliationTaxSettlementsDomestic	3528000	usd
CY2021	us-gaap	Income Tax Reconciliation Tax Settlements Domestic IncomeTaxReconciliationTaxSettlementsDomestic	1255000	usd
CY2021	us-gaap	Income Tax Reconciliation Tax Settlements Foreign IncomeTaxReconciliationTaxSettlementsForeign	2812000	usd
CY2022	us-gaap	Income Tax Reconciliation Tax Settlements IncomeTaxReconciliationTaxSettlements	4435000	usd
CY2021Q4	IGAP	Deferred Tax Assets Tax Vacation Accrual DeferredTaxAssetsTaxVacationAccrual	6000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	174000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	11805000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	11654000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	11979000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	11660000	usd
CY2022Q4	IGAP	Deferred Tax Asset Valuation Allowance DeferredTaxAssetValuationAllowance	11979000	usd
CY2021Q4	IGAP	Deferred Tax Asset Valuation Allowance DeferredTaxAssetValuationAllowance	11660000	usd
CY2022	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1

Files In Submission

Name	View Source	Status
igap-20221231_pre.xml	Edgar Link	unprocessable
0001493152-23-010356-index-headers.html	Edgar Link	pending
0001493152-23-010356-index.html	Edgar Link	pending
0001493152-23-010356.txt	Edgar Link	pending
0001493152-23-010356-xbrl.zip	Edgar Link	pending
ex23-1.htm	Edgar Link	pending
ex23-1_001.jpg	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
ex32-2.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-k.htm	Edgar Link	pending
igap-20221231.xsd	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
igap-20221231_cal.xml	Edgar Link	unprocessable
igap-20221231_def.xml	Edgar Link	unprocessable
igap-20221231_lab.xml	Edgar Link	unprocessable
form10-k_htm.xml	Edgar Link	completed
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$GCTK
GlucoTrack Inc Stock $gctk

2023 Q1 Form 10-K Financial Statement

#000149315223010356 Filed on March 31, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$GCTK GlucoTrack Inc Stock $gctk

2023 Q1 Form 10-K Financial Statement

#000149315223010356 Filed on March 31, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$GCTK
GlucoTrack Inc Stock $gctk